Crystal Eye Studio / Shutterstock.com
The US Supreme Court yesterday (March 9) refused to hear a case between Californian pharmaceutical company Gilead and India-based Natco that concerns ‘double patenting’.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Supreme Court, Gilead, Natco, obviousness-type double patenting, Tamiflu